Collaborators
Yosuke Hirakawa, Hitoshi Sugiyama, Yoshio Terada, Takashi Shigematsu, Tadashi Sofue, Masanori Emoto, Yusuke Suzuki, Shinichi Araki, Kazuhiko Ohe, Mihoko Okada, Seiji Itano, Akira Nishiyama, Eiichiro Kanda, Hiromi Kataoka, Takako Nakahara, Yusei Ooi.
Conflict of Interest Statement
YY received grants or contracts from Daiichi-Sankyo, honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Torii, and Support for attending meetings from Bayer. JW received grants or contracts from Bayer, Chugai, Kyowa Kirin, Otsuka, Shionogi, Sumitomo, and Mitsubishi Tanabe, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kyowa Kirin, Novo Nordisk Pharma, and Mitsubishi Tanabe. TY is board member of Japanese Society of Nephrology (unpaid). IN received grants or contracts from Bayer Yakuhin, Terumo, Chugai Pharmaceutical, Kyowa Kirin, Daiichi-Sankyo, Sumitomo Pharma, Amicus Thepeuticus, Terumo, Kaneka, Otsuka Pharmaceutical, Astellas Pharma, and Ono Pharmaceutical, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Sanofi, Otsuka Pharmaceutical, Bayer, and Kyowa Kirin. KY received grants or contracts from Kyowa-Kirin and Tanabe-Mitsubishi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kyowa-Kirin and Tanabe-Mitsubishi, Mochida, Astra-Zeneca, and Asteras. and Otsuka. MN received grants or contracts from Kyowa-Kirin, Tanabe-Mitsubishi, Chugai, Boehringer Ingelheim, Torii, Takeda, Daiichi-Sankyo, and JT, consulting fees from Kyowa-Kirin, and Tanabe-Mitsubishi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kyowa-Kirin, Tanabe-Mitsubishi, Bayer, Astellas, JT, and Astra Zeneca. NK received consulting fees from Kyowa-Kirin and NovoNordisk Pharma, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer Pharma, AstraZeneca, Ono Pharma, Novartis Phamak, Kyowa-Kirin, Boehringer Ingelheim Japan, Astellas Pharma, and Novo Nordisk Pharma, Participation on a Data Safety Monitoring Board or Advisory Board from Novo Nordisk Pharma and AstraZeneka, and board member of Japan Kidney Association. HO received grants or contracts from Kyowa Kirin, Torii Pharma, and Kissei Pharma, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, Kyowa Kirin, Daiichi Sankyo, AstraZeneca, Bayer AG, Mitsubishi Tanabe Pharma, Torii Pharma, Ono Pharma, Boehringer Ingelheim International GmbH, Participation on a Data Safety Monitoring Board or Advisory Board from Boehringer Ingelheim International GmbH, Daiichi Sankyo, Elli Lily, Mitsubishi Tanabe Pharma, Kissei Pharma, and board member of Japanese Society of Nephrology (unpaid).
Authors’ Contributions
- Conception and design: Yuichiro Yano; Hajime Nagasu; Naoki Kashihara; and Hirokazu Okada.
- Analysis of data: Hiroshi Kanegae.
- Interpretation of data: Zannatun Nyma; Kaori Kitaoka; Yuichiro Yano; Hiroshi Kanegae; Nomin Bayaraa; Seiji Kishi; Hajime Nagasu; Toshiaki Nakano; Jun Wada; Shoichi Maruyama; Naoki Nakagawa; Kouichi Tamura; Takashi Yokoo; Motoko Yanagita; Ichiei Narita; Kunihiro Yamagata; Takashi Wada; Kazuhiko Tsuruya; Naoki Nakajima; Yoshitaka Isaka; Masaomi Nangaku; Naoki Kashihara; and Hirokazu Okada.
- Drafting of the manuscript: Zannatun Nyma; Kaori Kitaoka; Yuichiro Yano; and Nomin Bayaraa.
- Critical revision for important intellectual content: Seiji Kishi; Hajime Nagasu; Toshiaki Nakano; Jun Wada; Shoichi Maruyama; Naoki Nakagawa; Kouichi Tamura; Takashi Yokoo; Motoko Yanagita; Ichiei Narita; Kunihiro Yamagata; Takashi Wada; Kazuhiko Tsuruya; Naoki Nakajima; Yoshitaka Isaka; Masaomi Nangaku; Naoki Kashihara; and Hirokazu Okada.
- Final approval of the submitted manuscript: Zannatun Nyma; Kaori Kitaoka; Yuichiro Yano; Hiroshi Kanegae; Nomin Bayaraa; Seiji Kishi; Hajime Nagasu; Toshiaki Nakano; Jun Wada; Shoichi Maruyama; Naoki Nakagawa; Kouichi Tamura; Takashi Yokoo; Motoko Yanagita; Ichiei Narita; Kunihiro Yamagata; Takashi Wada; Kazuhiko Tsuruya; Naoki Nakajima; Yoshitaka Isaka; Masaomi Nangaku; Naoki Kashihara; and Hirokazu Okada.
Funding
This work was supported in part by Japan Agency for Medical Research and Development through Grant Number 20319844 and 19188716, Ministry of Health, Labour and Welfare of Japan through Grant Number JPMH 23FC0201, JPMH22FD2001 and JPMH22FD1001 to HO and NK@. AMED-Project for Elucidating and Controlling Mechanisms 2017-2021, AMED (Platform Program for Promotion of Genome Medicine) 2018-2023, AMED-CREST Understanding of Pathophysiological Processes and Discovery of Medical Technology Seeds through Spatiotemporal Research of Tissue Adaptation and Repair Mechanisms 2019-2024, Grant-in-Aid for challenging Exploratory Research 2021-2022, 2023-2024, AMED (Translational Research, Seeds A) 2020-2021, 2022, Grant-in-Aid for Scientific Research(B) 2020-2022, 2023-2025, Grant-in-Aid for Scientific Research(C) 2021-2023, AMED Moonshot Research and Development Program 2021-2025, AMED-Project for Elucidation of the role of tertiary lymphoid tissue in human kidney disease and its potential as a target for therapeutic intervention 2022-2024 to MY.
Data Availability Statement
The data underlying this article will be shared on reasonable request to the corresponding author.